FLOW
2024
Semaglutide and Kidney Outcomes in Type 2 Diabetes with Chronic Kidney Disease
In 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.
Result
Efficacy: Kidney failure, ≥50% eGFR decline, or renal or CV deathHR 0.76 (95% CI 0.66-0.88) · P = 0.0003
Below 1 favours semaglutide, above 1 favours placebo.
Also reported: All-cause mortality HR 0.80.
- Subtopic
- GLP-1 RA
- Design
- Double-blind RCT, stopped early
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Also listed in
- Diabetes & cardiometabolic
- Source
- Perkovic V, et al. N Engl J Med. 2024;391(2):109-121.doi 10.1056/NEJMoa2403347
Discussion & critique
First GLP-1-agonist trial with a dedicated renal hard endpoint; the benefit was numerically attenuated in the ~16% on background SGLT2 inhibitors.